comparemela.com

Latest Breaking News On - Anticancer therapies congress - Page 5 : comparemela.com

Onxeo S.A.: Onxeo's New Preclinical Data Confirm the Relevance of Combining AsiDNA With PARP Inhibitors in Treating Homologous Recombination Proficient Tumors

These pioneering data were presented at ESMO Targeted Anticancer Therapies Congress 2022 Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX, First North Copenhagen: ONXEO), ("Onxeo" or

Paris
France-general
France
Copenhagen
Køavn
Denmark
Wael-jdey
Nicolas-merigeau
Onxeo-sa-euronext
Valerie-leroy
Emmanuel-huynh
Anticancer-therapies-congress

GT Biopharma Presented Preclinical Data Demonstrating Novel Mesothelin-Targeted TriKE® Driving Cytotoxicity Across All Stages of Non-Small Cell Lung Cancer at ESMO TAT 2022

/PRNewswire/ GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the.

Brisbane
Queensland
Australia
Jeff-miller
Corey-davis
David-castaneda
Gregory-berk
Exchange-commission
Prnewswire-gt-biopharma-inc
Source-gt-biopharma-inc
Anticancer-therapies-congress
University-of-minnesota

GT Biopharma Presented Preclinical Data Demonstrating Novel Mesothelin-Targeted TriKE® Driving Cytotoxicity Across All Stages of Non-Small Cell Lung Cancer at ESMO TAT 2022

/PRNewswire/ GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the.

Brisbane
Queensland
Australia
Jeff-miller
Corey-davis
David-castaneda
Gregory-berk
Exchange-commission
Prnewswire-gt-biopharma-inc
Source-gt-biopharma-inc
Anticancer-therapies-congress
University-of-minnesota

IN8bio to present at March Investor and Scientific Conferences

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Prague
Praha
Hlavníesto
Czech-republic
Robert-flamm
Kate-rochlin
David-buck
Anticancer-therapies-congress
Company-contact
Burns-mcclellan-inc
Health-care-conference
Meeting-of-the-european-society-for-blood

Tango Therapeutics Announces Presentation of TNG908

CAMBRIDGE, Mass., March 03, 2022 (GLOBE NEWSWIRE) Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and.

Cambridge
Cambridgeshire
United-kingdom
Joshuar-mansbach
Sam-martin-michael-barron
Tango-therapeutics-inc
Anticancer-therapies-congress
European-society-for-medical-oncology
Nasdaq
Medical-oncology
Targeted-anticancer-therapies-congress
Quarterly-report

vimarsana © 2020. All Rights Reserved.